Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14‐year multicenter study
Cancer Medicine · 2023
DOI: 10.1002/cam4.6586 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yanna Ye und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Midwifery, Faculty of Health, Dongguan Polytechnic, Dongguan, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Adenocarcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
To compare the oncological outcomes of radical chemotherapy (R‐CT), abdominal radical hysterectomy (ARH), and neoadjuvant chemotherapy and radical surgery (NACT) for International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIIC cervical cancer, according to histological types: squamous cell carcinoma (SCC) and adenocarcinoma (AC)/adenosquamous cell carcinoma (ASC).
Methods
A comparison of 5‐year overall survival (OS) and disease‐free survival (DFS) was performed for the SCC and AC/ASC subgroups for the three initial treatments, assessed using Kaplan–Meier and Cox proportional hazards regression analysis and validated using propensity score matching (PSM).
Results
The study included 4086 patients: R‐CT, n = 1913; ARH, n = 1529; and NACT, n = 644. AC/ASC had a lower survival rate (63.7%) than SCC (73.6%) and a higher recurrence and mortality rate (36.3% and 26.4%, respectively). The 5‐year OS and DFS rates were different in the SCC group for R‐CT, ARH, and NACT (OS: 69.8% vs. 80.8% vs. 73.0%, p < 0.001; DFS: 66.7% vs. 70.7% vs. 56.4%, p < 0.001), also in the AC/ASC group (OS: 46.1% vs. 70.6% vs. 55.6%, p < 0.001; DFS: 42.7% vs. 64.6% vs. 40.8%, p < 0.001). As for initial treatment, survival outcomes were worse for AC/ASC treated with R‐CT and ARH than for SCC (both p < 0.05), with no group differences between the two treated with NACT.
Conclusion
Initial treatment influences oncological prognosis for patients with FIGO 2018 stage IIIC cervical cancer. ARH is an alternative treatment for stage IIIC cervical SCC and AC/ASC, and NACT needs to be chosen with caution, moreover, R‐CT for AC/ASC requires careful selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Midwifery, Faculty of Health, Dongguan Polytechnic, Dongguan, China.
- Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of General Surgery, China-Japan Friendship Hospital, Beijing, China.
- Department of Obstetrics and Gynecology, Xijing Hospital of Airforce Medical University, Xian, China.
- Department of Gynecologic Oncology, Shanxi Provincial Cancer Hospital, Taiyuan, China.
- Department of Obstetrics and Gynecology, Xinqiao Hospital, Army Medical University, Chongqing, China.
ORCID-Profile: Yanna Ye, Chunlin Chen
Zitieren
APA
Ye, Y., Zhang, G., Li, Z., Chen, B., Zhao, H., Yang, Y., Wang, L., Yao, J., Chen, X., Huang, Y., Lang, J., Liu, P., & Chen, C. (2023). Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14‐year multicenter study. Cancer Medicine. https://doi.org/10.1002/cam4.6586
Vancouver
Ye Y, Zhang G, Li Z, Chen B, Zhao H, Yang Y, et al. Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14‐year multicenter study. Cancer Medicine. 2023. doi:10.1002/cam4.6586
BibTeX
@article{Ye2023,
author = {Ye, Yanna and Zhang, Guochao and Li, Zhiqiang and Chen, Biliang and Zhao, Hongwei and Yang, Ying and Wang, Li and Yao, Jilong and Chen, Xiaolin and Huang, Yahong and Lang, Jinghe and Liu, Ping and Chen, Chunlin},
title = {Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14‐year multicenter study},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6586}
}
EUVIMED